ID

26682

Description

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Standard of care medications

Mots-clés

  1. 27/08/2017 27/08/2017 -
  2. 23/10/2017 23/10/2017 -
  3. 12/12/2017 12/12/2017 -
Détendeur de droits

GlaxoSmithKline

Téléchargé le

23 octobre 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Standard of care medications GSK study Chronic Coronary Heart Disease NCT00799903

Standard of care medications GSK study Chronic Coronary Heart Disease NCT00799903

Standard of care medications
Description

Standard of care medications

1. Was the subject regularly taking STATIN therapy for 8 weeks or more prior to randomisation?
Description

STATIN therapy prior to randomisation

Type de données

boolean

2. Was the subject taking STATIN therapy at the time of randomisation?
Description

STATIN therapy at randomisation

Type de données

boolean

If no, indicate reason
Description

no STATIN therapy at randomisation reason

Type de données

text

If other reason, specify:
Description

no STATIN therapy at randomisation other reason

Type de données

text

3. Was the subject regularly taking ASPIRIN therapy for 8 weeks or more prior to randomisation?
Description

ASPIRIN therapy prior to randomisation

Type de données

boolean

4. Was the subject taking ASPIRIN at the time of randomisation?
Description

ASPIRIN at randomisation

Type de données

boolean

If no, indicate reason:
Description

no ASPIRIN at randomisation reason

Type de données

text

If other reason, specify:
Description

no ASPIRIN at randomisation other reason

Type de données

text

5. Is the subject regularly taking any P2Y12 inhibitors (i.e. thienopyridines)?
Description

P2Y12 inhibitors

Type de données

boolean

If no, indicate reason:
Description

no P2Y12 inhibitors reason

Type de données

text

If other reason, specify:
Description

no P2Y12 inhibitors other reason

Type de données

text

6. Is the subject taking a beta-blocker?
Description

beta-blocker

Type de données

boolean

If no, indicate reason:
Description

no beta-blocker reason

Type de données

text

If other reason, specify:
Description

no beta-blocker other reason

Type de données

text

7. Is the subject taking an ACE inhibitor?
Description

ACE inhibitor

Type de données

boolean

If no, indicate reason:
Description

no ACE inhibitor reason

Type de données

text

If other reason, specify:
Description

no ACE inhibitors other reason

Type de données

text

8. Is the subject taking an ARB?
Description

ARB

Type de données

boolean

If no, indicate reason:
Description

no ARB reason

Type de données

text

If other reason, specify:
Description

no ARB other reason

Type de données

text

9. Is the subject taking any other renin-angiotensin-aldosterone system-targeted medication?
Description

renin-angiotensin-aldosterone system-targeted medication

Type de données

boolean

If no, indicate reason:
Description

no renin-angiotensin-aldosterone system-targeted medication reason

Type de données

text

If other reason, specify:
Description

no renin-angiotensin-aldosterone system-targeted medication other reason

Type de données

text

Similar models

Standard of care medications GSK study Chronic Coronary Heart Disease NCT00799903

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Standard of care medications
STATIN therapy prior to randomisation
Item
1. Was the subject regularly taking STATIN therapy for 8 weeks or more prior to randomisation?
boolean
STATIN therapy at randomisation
Item
2. Was the subject taking STATIN therapy at the time of randomisation?
boolean
Item
If no, indicate reason
text
Code List
If no, indicate reason
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
Item
If other reason, specify:
text
Code List
If other reason, specify:
ASPIRIN therapy prior to randomisation
Item
3. Was the subject regularly taking ASPIRIN therapy for 8 weeks or more prior to randomisation?
boolean
ASPIRIN at randomisation
Item
4. Was the subject taking ASPIRIN at the time of randomisation?
boolean
Item
If no, indicate reason:
text
Code List
If no, indicate reason:
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
no ASPIRIN at randomisation other reason
Item
If other reason, specify:
text
P2Y12 inhibitors
Item
5. Is the subject regularly taking any P2Y12 inhibitors (i.e. thienopyridines)?
boolean
Item
If no, indicate reason:
text
Code List
If no, indicate reason:
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
CL Item
Not clinically indicated (2)
no P2Y12 inhibitors other reason
Item
If other reason, specify:
text
beta-blocker
Item
6. Is the subject taking a beta-blocker?
boolean
Item
If no, indicate reason:
text
Code List
If no, indicate reason:
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
CL Item
Not clinically indicated (2)
no beta-blocker other reason
Item
If other reason, specify:
text
ACE inhibitor
Item
7. Is the subject taking an ACE inhibitor?
boolean
Item
If no, indicate reason:
text
Code List
If no, indicate reason:
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
CL Item
Not clinically indicated (2)
no ACE inhibitors other reason
Item
If other reason, specify:
text
ARB
Item
8. Is the subject taking an ARB?
boolean
Item
If no, indicate reason:
text
Code List
If no, indicate reason:
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
CL Item
Not clinically indicated (2)
no ARB other reason
Item
If other reason, specify:
text
renin-angiotensin-aldosterone system-targeted medication
Item
9. Is the subject taking any other renin-angiotensin-aldosterone system-targeted medication?
boolean
Code List
If no, indicate reason:
CL Item
Subject is intolerant or clinically contraindicated (1)
CL Item
Other (OT)
CL Item
Not clinically indicated (2)
no renin-angiotensin-aldosterone system-targeted medication other reason
Item
If other reason, specify:
text

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial